FMP
Millendo Therapeutics, Inc.
MLND
NASDAQ
Inactive Equity
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
1.06 USD
-0.06000006 (-5.66%)
MLND Financial Statements
Quarter
2021 Q2
2021 Q1
2020 Q2
2020 Q1
Total Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
6.79M
8.56M
10.6M
12.13M
Research and Development
4.23M
2.15M
6.47M
7.54M
Selling, General & Administrative Expenses
2.56M
6.41M
4.14M
4.59M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
2.56M
6.41M
4.14M
4.59M
Other Expenses
2.56M
0
0
0
Operating Income
-6.79M
-8.56M
-10.6M
-12.13M
Total Other Income/Expenses Net
-273k
173k
-68k
137k
Income Before Tax
-7.06M
-8.39M
-10.67M
-12M
Income Tax
3k
173k
-68k
-25k
Net Income
-7.06M
-8.39M
-10.67M
-12M
Basic EPS
-5.57
-6.61
-8.43
-9.76
EPS Diluted
-5.57
-6.61
-8.43
-9.76
Basic Average Shares
1.27M
1.27M
1.27M
1.23M
Diluted Average Shares
1.27M
1.27M
1.27M
1.23M
EBITDA
-6.62M
-8.21M
-10.38M
-11.88M
Retained Earning Schedule
Quarter
2021 Q2
2021 Q1
2020 Q2
2020 Q1
Retained Earnings (Previous Year)
-253.45M
-231.32M
-220.65M
-184.32M
Net Income
-7.06M
-8.39M
-10.67M
-12M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
0
-253.45M
-231.32M
-220.65M
Other Distributions
253.45M
-22.13M
-10.67M
-36.33M
PPE Schedule
Quarter
2021 Q2
2021 Q1
2020 Q2
2020 Q1
Gross PPE
4.89M
2.01M
2.62M
2.87M
Annual Depreciation
165k
176k
289k
280k
Capital Expenditure
-84k
0
0
-26k
Net PPE
4.81M
1.84M
2.33M
2.61M
Intangible and Goodwill Schedule
Quarter
2021 Q2
2021 Q1
2020 Q2
2020 Q1
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
